Group 1 - The core point of the article highlights the performance of the China Europe Medical Innovation Stock C fund, which has a latest net value of 1.1626 yuan, reflecting a decrease of 1.43% [1] - The fund's performance over the past month shows a return of 3.72%, ranking 37 out of 541 in its category; over the past three months, it has achieved a return of 20.12%, ranking 10 out of 539; and since the beginning of the year, it has returned 17.16%, ranking 13 out of 537 [1] - The top ten holdings of the fund account for a total of 75.62%, with significant positions in companies such as WuXi AppTec (10.35%), Kelun-Biotech (10.15%), and WuXi Biologics (9.82%) [1] Group 2 - The China Europe Medical Innovation Stock C fund was established on February 28, 2019, and as of March 31, 2025, it has a total scale of 3.524 billion yuan [1] - The fund is managed by Guo Lan, who has extensive experience in the investment management field, having previously worked at Guotai Junan Securities and Minsheng Zhiyin Fund Management [2]
4月25日中欧医疗创新股票C净值下跌1.43%，近1个月累计上涨3.72%
Sou Hu Cai Jing·2025-04-25 12:35